0.89
-0.0342(-3.71%)
Currency In USD
| Previous Close | 0.92 |
| Open | 0.92 |
| Day High | 0.96 |
| Day Low | 0.85 |
| 52-Week High | 3.65 |
| 52-Week Low | 0.37 |
| Volume | 938,326 |
| Average Volume | 11.26M |
| Market Cap | 18.04M |
| PE | -0.64 |
| EPS | -1.38 |
| Moving Average 50 Days | 1.09 |
| Moving Average 200 Days | 0.96 |
| Change | -0.03 |
If you invested $1000 in Imunon, Inc. (IMNN) 10 years ago, it would be worth $1.74 as of June 25, 2025 at a share price of $0.888. Whereas If you bought $1000 worth of Imunon, Inc. (IMNN) shares 5 years ago, it would be worth $14.47 as of June 25, 2025 at a share price of $0.888.
For more details, use our stock calculator to calculate how much you would've made investing different amounts on specific dates.
IMUNON Presents Positive Phase 2 Translational Data of IMNN-001 in Advanced Ovarian Cancer at ESMO Gynaecological Cancers Congress 2025
GlobeNewswire Inc.
Jun 18, 2025 12:05 PM GMT
ASCO 2025 overall survival data bolster IMNN-001’s potential in advanced ovarian cancer, supported by robust translational results at ESMO Results from OVATION 2 Study reinforce IMNN-001 mechanism of action, producing IL-12 and key anti-cancer immune
IMUNON Announces PlaCCine® DNA Vaccine Technology Abstract Selected for Oral Presentation at 10th International Conference on Vaccines Research & Development™
GlobeNewswire Inc.
Jun 17, 2025 12:05 PM GMT
Clinical Data Highlight PlaCCine’s Six-Month Durability, Temperature Stability, and Manufacturing Advantages Over mRNA Vaccines IMUNON Seeks Strategic Partner for PlaCCine® to Advance Novel Technology and Fund Core Pipeline with Non-Dilutive Capital
IMUNON to Present at the Zacks SCR Life Sciences Virtual Investor Forum on June 12th
GlobeNewswire Inc.
Jun 05, 2025 12:00 PM GMT
LAWRENCEVILLE, N.J., June 05, 2025 (GLOBE NEWSWIRE) -- IMUNON, Inc. (NASDAQ: IMNN), a clinical-stage company in Phase 3 development with its DNA-mediated immunotherapy, today announced that Stacy Lindborg, Ph.D., President and Chief Executive Offic